Project Grant R01FD007605
Award Date
9/15/22
Completion Date
8/31/26
Dollars Obligated
$3.2M
Funding Federal Agency
Center for Drug Evaluation and Research
Awarding Federal Agency
FDA Office of Acquisition and Grant Services
Federal Grant Program
93.103
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This R03 project grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate the use of non-genotoxic hematopoietic stem cell transplantation (HSCT) as a potential treatment for ataxia telangiectasia (A-T), a genetic disorder characterized by neurodegeneration, immune deficiencies, and increased lymphoma risk. The $117,375 project, awarded to Emory University, has a period of performance from...
The U.S. Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $1,984,636 Project Grant to The Children's Hospital of Philadelphia (CHOP) to conduct research on identifying and reversing functional cerebellar circuit dysfunctions in Friedreich's ataxia mice. The grant, awarded on September 1, 2024, will support this research project over a 4-year period until August 31, 2028. As a leading pediatric research institution, CHOP will leverage...
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $1,273,300 Project Grant to The Children's Hospital of Philadelphia (CHOP) to conduct research on identifying and reversing functional cerebellar circuit dysfunctions in a mouse model of Friedreich's ataxia. The grant, with a performance period from September 1, 2024 to August 31, 2028, will support CHOP's pioneering research efforts to advance understanding and treatment of this...
This Cooperative Agreement award from the Food and Drug Administration (FDA) Research program (CFDA 93.103) provides $1,100,000 to the University of Rochester to evaluate the reliability, validity, and meaningfulness of digital measures of daily living mobility (gait) and chorea in individuals with early-stage Huntington's disease (HD). The project aims to: Demonstrate the construct validity and test-retest reliability of real-world gait, chorea, daily physical activity, heart rate...
The Johns Hopkins University received a $2,455,671.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to develop an AAV-based gene therapy for amyotrophic lateral sclerosis (ALS). The award, effective June 1, 2024 through May 31, 2027, will enable Johns Hopkins to conduct innovative biomedical research and advance therapeutic solutions for this neurological disorder. The federal grant funding supports the university's...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $855,728 to The Johns Hopkins University to identify abnormally regulated lipid pathways in human motor neuron and fly models, with the goal of developing a new pharmacological drug candidate. The award period runs from Sep 1, 2024 to Aug 31, 2026. As a leading research university, Johns Hopkins has a strong track record of federal grant...
This $1,536,075 federal Project Grant awarded by the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development program) supports proteomics research on atrioventricular septal defect in Down syndrome at The Johns Hopkins University. The award period runs from September 1, 2024 to August 31, 2028. The funding will allow Johns Hopkins to conduct basic, translational, and clinical research to improve understanding and treatment of this condition, which is a priority area for...
The federal Cooperative Agreement award number UM1TR004926, totaling $9,740,327.00, was granted by the National Center for Advancing Translational Sciences (NCATS) to The Johns Hopkins University to support the Johns Hopkins Institute for Clinical and Translational Research. This NCATS grant program (CFDA 93.350) funds research and development initiatives aimed at accelerating the translation of scientific discoveries into medical treatments and interventions. Through this Cooperative Agreement,...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $396,324 to The Johns Hopkins University to develop novel N-acetylaspartate (NAT8L) inhibitors for the treatment of Canavan disease, a rare inherited neurological disorder. The key objectives are to: 1) conduct structure-activity relationship studies to optimize a lead...
The U.S. Department of the Army Medical Command, through the Military Medical Research and Development (CFDA 12.420) federal grant program, awarded a $798,272.00 Project Grant to The Johns Hopkins University on March 15, 2025. The grant supports research to test the use of Wnt inhibitors as a therapeutic approach to reverse TDP-43 dysfunction in amyotrophic lateral sclerosis (ALS). The research will be conducted at Johns Hopkins University in Baltimore, Maryland over a 2-year period, with a...